| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.9 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |